Melanoma is the most deadly skin cancer. According to data collected between 2004 and 2010, only 16% of Americans with metastatic melanoma, including people of all ages and races, and both genders, survive for 5 years or more after diagnosis.
Where once limited treatment options existed for patients with CLL, medical oncologists now have a plethora of agents from which to choose, making disease management in CLL more effective with fewer toxicities.
The attenuated vaccinia virus, GL-ONC1, demonstrated safety and clinical benefit when delivered intravenously with concurrent chemoradiation therapy in patients who have locoregionally advanced head and neck carcinoma (LA-HNC).
Lowell B. Anthony, MD, discusses the potential benefits of cabozantinib for patients for different types of patients with neuroendocrine tumors.
Research may hasten the effort to determine which strains of cancer will eventually become resistant to chemotherapy, paving the way for developing more effective targeted treatments.
A SOHO 2022 presentation by Jason Westin, MD will focus on t on 2 main categories of novel agents that manipulate the immune system to better target aggressive lymphomas.
The goal of precision medicine is to advance medical and scientific discoveries to offer more tailored, precise, and accurate health interventions to maximize the health benefits for patients.
Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.
Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.
Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses diagnostic platforms for lung cancer.
Immune checkpoint inhibitors as monotherapy and in combinations regimens are producing promising efficacy data in metastatic head and neck cancers, depite struggles in finding the right treatment settings and patient population subsets.
Agents that inhibit SHP2 attack cancer cells in a way that is distinct from other therapies, and data showing the potential efficacy of such therapies, are fueling more research.
Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival (OS) for patients with early-stage hepatocellular carcinoma.
Malignant mesothelioma is an uncommon malignancy of the pleura that is usually associated with asbestos exposure.
Mark A. Rubin, MD, director, Institute for Precision Medicine, Weill Cornell Medical College, discusses immunotherapy in the field of genitourinary cancers.
Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.
Mark R. Middleton, MD, PhD, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.
Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia.
Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Targeted Therapies in Oncology spoke with Martin J. Edelman, MD, do uncover what is next for small cell lung cancer after PD-1 inhibitor indication have been withdrawn.
During a 2013 discussion on treating NSCLC, a group of oncologists were asked what share of cancer patients have access to molecular testing. The answers varied: One said he guessed 40% to 50%, another said "a large minority."
Across therapy vehicles, agents targeting the B-cell maturation antigen have emerged as promising potential therapies in the multiple myeloma treatment paradigm. Following the 2019 American Society of Hematology Annual Meeting & Exposition, experts reflect on what these new advances mean for the field of oncology care.